Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Faldaprevir and deleobuvir for HCV genotype 1 infection.

The New England journal of medicine - 15 Aug 2013

Zeuzem Stefan, Soriano Vincent, Asselah Tarik, Bronowicki Jean-Pierre, Lohse Ansgar W, Müllhaupt Beat, Schuchmann Marcus, Bourlière Marc, Buti Maria, Roberts Stuart K, Gane Ed J, Stern Jerry O, Vinisko Richard, Kukolj George, Gallivan John-Paul, Böcher Wulf-Otto, Mensa Federico J

Abstract excerpt

BACKGROUND: Interferon-free regimens would be a major advance in the treatment of patients with chronic hepatitis C virus (HCV) infection. METHODS: In this phase 2b, randomized, open-label trial of faldaprevir (a protease inhibitor) and deleobuvir (a nonnucleoside polymerase inhibitor), we random...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to DNA-Directed RNA Polymerases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leucine

Share to Oligopeptides

Share to Proline

Share to Protease Inhibitors

Share to Quinolines

Share to Thiazoles

Source

Identifiers

PMID: 23944300
DOI: 10.1056/NEJMoa1213557

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23944300-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Faldaprevir and deleobuvir for HCV genotype 1 infection.PMID 23944300Read ↗

Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study.Semantic proximity Read ↗

HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.Semantic proximity Read ↗

Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.Semantic proximity Read ↗

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection.Semantic proximity Read ↗

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.Semantic proximity Read ↗

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.Semantic proximity Read ↗

Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.Semantic proximity Read ↗

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.Semantic proximity Read ↗

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.Semantic proximity Read ↗

Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.